The microbiome continuously shapes its environment through a complex set of interactions, and the microbial flora within and outside the human body has an essential relationship to an organism’s health status. For instance, dysbiosis in the gut microflora is an established contributor to the development of pathological conditions such as chronic inflammatory bowel diseases, type 2 diabetes, and colorectal cancer. In the drug discovery industry, scientists must be proactive in detecting changes in the intestinal microbiome in response to novel therapeutics. Changes to the microbiome associated with probiotic and prebiotic administration must be carefully monitored. Characterizing changes to the gut microbiome whether by metabolic, enzymatic, biomarker, or genomic approaches is fraught with difficulty and has a high assay development and validation cost. Therefore, many companies have looked to partner with research organizations that have success with innovative microbiome analysis tools.

In this webinar, our distinguished speakers, Dr. David Kwok and Dr. David Willoughby discuss current biomarker identification and metabolic evaluation techniques of the human gut microbiome, as well as metagenomic sequencing modalities utilized to streamline results for expedited interpretation and analysis.

Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."

Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion, metastasis, disease progression and mortality, thus serving as a novel cancer biomarker. In this paper, we develop and validate an LC-MS/MS method for the quantification of fascin proteins in human serum.